Manfred Rüdiger

Manfred Rüdiger was the founder of Ariceum Therapeutics GmbH, founded in 2021, where the title held was Chief Executive Officer from 2021 to 2025.
Current jobs include Vice Chairman-Supervisory Board at 4SC AG since 2022, Chairman-Supervisory Board at Minaris Regenerative Medicine GmbH, Chairman at Thermosome GmbH, and Director at G2M Cancer Drugs AG.
Former jobs include Chief Executive Officer at igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH (2004–2005), Chief Executive Officer at Affectis Pharmaceuticals AG (2011–2013), Chief Executive Officer at Kiadis Pharma BV (2011–2015), Chief Executive Officer & Partner at t2cure GmbH (2006–2009), Chief Executive Officer at Kiadis Pharma NV (2015–2017), Chief Executive Officer at Igeneon AG (2004–2005), Chief Executive Officer at CatalYm GmbH (2018–2021), Managing Director at Kiadis Pharma Canada, Inc. (2011–2017), Managing Director at Kiadis Pharma Deutschland GmbH (2014–2017), Chief Operating Officer at Aphton Corp., Chief Executive & Scientific Officer at Cardion GmbH (1998–2003), Assistant Professor at Technische Universität Braunschweig (1994–1998), Partner at LSP Services Deutschland GmbH (2010–2014), and Member-Supervisory Board at HeartBeat.bio AG.
Education includes an undergraduate degree from Eberhard Karls Universität Tübingen in 1991 and a doctorate from Max Planck Institute for Biophysical Chemistry in 1994.